Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Columbus Memory Center LLC

Neither a doctor nor a teaching hospital

Research payments

$5,789,384

178 payments

Through program year 2025, Columbus Memory Center LLC is reported as receiving $5,789,384 in research payments, across 178 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $425,392 44
2024 Research $2,632,244 79
2023 Research $2,681,524 47
2022 Research $50,224 8

Breakdown

Who paid Research payments · program years 2022–2025
  1. Eli Lilly and Company $2,305,297 15 payments
  2. AbbVie, Inc. $1,986,647 148 payments
  3. Roche Diagnostics Operations, Inc. $1,473,216 14 payments
  4. Genentech, Inc. $24,225 1 payment
Studies the money was for Research payments · program years 2022–2025
  1. Rd006263 $1,473,216 14 payments
  2. A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer Disease $965,040 66 payments
  3. A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease $538,690 32 payments
  4. Assessment of Safety Tolerability and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $477,327 1 payment
  5. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $395,008 1 payment
  6. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $392,094 1 payment
  7. A Phase 3 Open-Label Parallel-Group 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-Avwa in Participants With Early Symptomatic Alzheimer's Disease $327,162 1 payment
  8. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $318,823 3 payments
  9. Assessment of Safety, Tolerability, and Efficacy Measured By Amyloid Reduction of Ly3372993 in Early Symptomatic Alzheimer's Disease $234,550 2 payments
  10. A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimers Disease $181,457 7 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record